MedTrace Logo

Sustainability of Vaginal Estrogen Therapy in Postmenopausal Women

NCT02887885 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2022-04-27

No results posted yet for this study

Summary

Sustainability of vaginal ultra-low dose estrogen therapy in postmenopausal women

Conditions

  • Atrophy of Vagina
  • Postmenopause

Interventions

DRUG

Gynoflor

1 vaginal tablet daily for 12 days, followed by 3 vaginal tablets per week as maintenance therapy (Monday-Wednesday-Friday) for 6 weeks

Sponsors & Collaborators

  • Medinova AG

    collaborator INDUSTRY

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Petra Stute, Prof · University Hospital Berne

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-22
Primary Completion
2020-03-19
Completion
2020-04-10

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02887885 on ClinicalTrials.gov